Ulcerative colitis is no less common than peptic ulcer disease in our country. Although both are diseases of the gastrointestinal tract, the drugs for ulcerative colitis are fundamentally not the same as those for peptic ulcers and are almost as well known less than drugs for peptic ulcers. The following article will present about the drugs used in the treatment regimen for ulcerative colitis, invite you to learn.

As all professional societies recommend in their guidelines, patients with chronic HBV should receive antiviral prophylaxis when they start non-TNF-targeted biologics. In patients with resolved HBV, the rates of HBV reactivation without antiviral prophylaxis in patients receiving IL-23, IL-17, and JAK inhibitors were up to 2.3%, 4.2%, and 0%, respectively.